Susan Swain to Drug Synergism
This is a "connection" page, showing publications Susan Swain has written about Drug Synergism.
Connection Strength
0.099
-
Zhang X, Giangreco L, Broome HE, Dargan CM, Swain SL. Control of CD4 effector fate: transforming growth factor beta 1 and interleukin 2 synergize to prevent apoptosis and promote effector expansion. J Exp Med. 1995 Sep 01; 182(3):699-709.
Score: 0.031
-
Dubey C, Croft M, Swain SL. Costimulatory requirements of naive CD4+ T cells. ICAM-1 or B7-1 can costimulate naive CD4 T cell activation but both are required for optimum response. J Immunol. 1995 Jul 01; 155(1):45-57.
Score: 0.031
-
Swain SL. Role of BCGFII in the differentiation to antibody secretion normal and tumor B cells. J Immunol. 1985 Jun; 134(6):3934-43.
Score: 0.015
-
Swain SL, Howard M, Kappler J, Marrack P, Watson J, Booth R, Wetzel GD, Dutton RW. Evidence for two distinct classes of murine B cell growth factors with activities in different functional assays. J Exp Med. 1983 Sep 01; 158(3):822-35.
Score: 0.014
-
Murray PD, Swain SL, Kagnoff MP. Regulation of the IgM and IgA anti-dextran B1355S response: synergy between IFN-gamma, BCGF II, and IL 2. J Immunol. 1985 Dec; 135(6):4015-20.
Score: 0.004
-
Wetzel GD, Swain SL, Dutton RW, Kettman JR. Evidence for two distinct activation states available to B lymphocytes. J Immunol. 1984 Nov; 133(5):2327-32.
Score: 0.004